Table 3.
Predictive factors of 30-day mortality
| Survival | Death | |||
|---|---|---|---|---|
| Gender | Male | 49 (54.4%) | 41 (45.6%) | p = 0.488 |
| Female | 32 (56.1%) | 25 (43.9%) | ||
| Clinical presentation | Hematemesis | 38 (56.7%) | 29 (43.3%) | p = 0.423 |
| Others | 43 (53.8%) | 37 (46.2%) | ||
| Hemoglobin | <7 | 35 (63.6%) | 20 (36.4%) | p = 0.069 |
| >7 | 42 (49.4%) | 43 (50.6%) | ||
| Karnofsky status | 80–100 | 38 (64.4%) | 21 (35.6%) | p = 0.209 |
| 0–70 | 35 (55.6%) | 28 (44.4%) | ||
| Karnofsky status | 50–100 | 65 (61.9%) | 40 (38.1 %) | p = 0.186 |
| 0–40 | 8 (47.1%) | 9 (52.9%) | ||
| Etiology | Tumor and metastasis | 23 (56.1%) | 18 (43.9%) | p = 0.515 |
| Others | 58 (54.7%) | 48 (45.3%) | ||
| Actively bleeding | No | 52 (55.3%) | 42 (44.7%) | p = 0.540 |
| Yes | 29 (54.7%) | 24 (45.3%) | ||
| Chemotherapy | No | 38 (50.0%) | 38 (50.0%) | p = 0.131 |
| Yes | 43 (66.6%) | 28 (39.4%) | ||
| Rebleeding | No | 74 (56.5%) | 57 (43.5%) | p = 0.241 |
| Yes | 7 (43.8%) | 9 (56.2%) | ||